Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Interim phase II/III analysis points to benefits of Urocidin in non-muscle-invasive bladder cancer

May 31, 2011

Tigris Pharmaceuticals begins phase II trial of AFP-464 in ER-positive breast cancer

May 30, 2011

Peregrine Pharmaceuticals begins bavituximab combination trial in prostate cancer

May 30, 2011

Sulfated hyaluronic acid shows preclinical promise to treat prostate cancer

May 30, 2011

FDA approves IND for phase I trial of PWT-33597

May 27, 2011

Centella Therapeutics gains exclusive rights to antitumor agent CEN-209

May 27, 2011

Oncothyreon begins phase II portion of phase I/II trial of PX-866 with cetuximab

May 27, 2011

New sponge-derived anticancer polyketides described

May 27, 2011

Advantagene and FDA agree on SPA for phase III ProstAtak trial

May 26, 2011

Orion patents new androgen receptor modulators for prostate cancer

May 26, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...